Does securin expression have significance in prognostication of oral tongue cancer? A pilot study.
The proliferation marker, securin, is involved in the progression of many carcinomas. However, its expression in oral tongue squamous cell carcinoma (OTSCC) has not been previously studied. We examined securin expression by immunohistochemistry in OTSCC. A total of 93 cases treated for OTSCC were included in this study. Expression of securin in OTSCC was studied by immunohistochemistry of tissue microarrays (52 cases) and routine tumor sections (41 cases). Securin overexpression is significantly associated with higher tumor grade (P = 0.03). Overexpression of securin was observed more frequently in advanced stages of OTSCC than in earlier stages but the difference was not statistically significant. These findings suggest that overexpression of securin in OTSCC may be important during progression of this cancer. No significant association was found between securin expression and the prognosis of OTSCC.
Department of Pathology, University of Helsinki, Helsinki, Finland.|Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.
Ilkka
I
Heikkinen
Department of Pathology, University of Helsinki, Helsinki, Finland.|Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.|Institute of Dentistry, University of Misurata, Misurata, Libya.
Alhadi
A
Almangush
Department of Pathology, University of Helsinki, Helsinki, Finland.|Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.
Jaana
J
Hagström
Department of Oral Medicine and Diagnostic Sciences, King Saud University, Riyadh, Saudi Arabia.
Ibrahim O
IO
Bello
Department of Surgery, University of Oulu and Oulu University Hospital, Oulu, Finland.|Department of Pathology, University of Oulu and Oulu University Hospital, Oulu, Finland.
Joonas H
JH
Kauppila
Department of Otorhinolaryngology and Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Laura K
LK
Mäkinen
Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.|Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Caj
C
Haglund
Department of Medical Informatics and Statistics, University of Oulu, Oulu, Finland.
Pentti
P
Nieminen
Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.|Helsinki University Hospital, Helsinki, Finland.|Research Group of Cancer Research and Translational Medicine, Medical Faculty, University of Oulu, Oulu, Finland.|Medical Research Center, Oulu University Hospital, Oulu, Finland.
Tuula
T
Salo
Department of Pathology, University of Helsinki, Helsinki, Finland. ilmo.leivo@utu.fi.|Department of Pathology, University of Turku, Turku, Finland. ilmo.leivo@utu.fi.
Ilmo
I
Leivo
D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D011379:Prognosis; D064249:Securin / Q000378:metabolism*; D014062:Tongue Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology
D014408:Biomarkers, Tumor; D064249:Securin
Expression; Oral tongue squamous cell carcinoma; Prognosis; Securin